Home/Pipeline/NBTXR3 + anti-PD-1

NBTXR3 + anti-PD-1

Solid Tumors

Phase IActive (Study 1100)

Key Facts

Indication

Solid Tumors

Phase

Phase I

Status

Active (Study 1100)

Company

Nanobiotix

About Nanobiotix

Nanobiotix's mission is to transform cancer treatment by developing disruptive, physics-based nanotherapeutics, beginning with its lead radioenhancer candidate, NBTXR3. Key achievements include establishing a pivotal-stage global program in head and neck cancer and securing a landmark strategic collaboration with Janssen (Johnson & Johnson) for NBTXR3's co-development and commercialization. The company's strategy leverages its proprietary nanoparticle platform to create treatments that are biologically agnostic, aiming to improve radiotherapy outcomes and potentially prime anti-tumor immunity across a wide range of solid tumors.

View full company profile

Therapeutic Areas

Oncology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed
Undisclosed Whole Cell Vaccine Program(s)	Neuvogen	Pre-clinical	Active
SY-5609	Syros Pharmaceuticals	Phase 1/2	Discontinued
Not Specified (TCR Therapy)	T-Cure Bioscience	Phase 1	Active
B7-H3 Program	Ocean Biomedical	Discovery	Active